RayKnowChina Research Map
Shortlist

SuzhouSoochow University

First Affiliated Hospital of Soochow University

苏州大学附属第一医院

Listed for 29 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Soochow University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌8 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌22 papers led
  3. Hepatocellular carcinoma肝细胞癌73 papers led
  4. Stomach cancer胃癌90 papers led2 open trials led
  5. Retinoblastoma视网膜母细胞瘤2 papers led
  6. Chordoma脊索瘤2 papers led
  7. Osteosarcoma骨肉瘤4 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤6 papers led
  9. Neuroblastoma神经母细胞瘤1 paper led
  10. Multiple myeloma多发性骨髓瘤27 papers led7 open trials led
  11. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病12 papers led10 open trials led
  12. Aplastic anaemia再生障碍性贫血11 papers led2 open trials led
  13. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症6 papers led2 open trials led
  14. Beta thalassaemiaβ 地中海贫血1 paper led
  15. Haemophilia A血友病 A6 papers led
  16. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜5 papers led1 open trial led
  17. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病10 papers led
  18. Myasthenia gravis重症肌无力9 papers led
  19. Moyamoya disease烟雾病3 papers led
  20. Wilson disease肝豆状核变性(Wilson 病)2 papers led
  21. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  22. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  23. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  24. Fabry disease法布雷病3 papers led
  25. Duchenne muscular dystrophy杜氏肌营养不良2 papers led
  26. Behçet disease白塞病0 papers led
  27. IgA nephropathyIgA 肾病2 papers led
  28. Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
  29. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led

Not listed for: Hepatoblastoma, Ewing sarcoma, Atypical haemolytic uraemic syndrome, Fanconi anaemia, IgG4-related disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 8 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 2220232024: 2220242025: 002025

2 hospitals in Suzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueImaging & AIInduction / concurrent chemotherapy
Departments in papersENT / head & neck surgeryRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led8
  1. Expression and functional implications of YME1L in nasopharyngeal carcinoma.2024Cell death & diseaseFree full text
  2. Prognostic modeling for nasopharyngeal carcinoma (NC) undergoing concurrent chemoradiotherapy using clinical and enhanced MRI-Delta radiomics data: A preliminary study.2024Technology and health care : official journal of the European Society for Engineering and Medicine
  3. Syncope as the initial symptom in a patient with nasopharyngeal carcinoma: a case report.2023BMC cardiovascular disordersFree full text
  4. Overexpressed Gαi1 exerts pro-tumorigenic activity in nasopharyngeal carcinoma.2023Cell death & diseaseFree full text
  5. CircKIAA0368 Promotes Proliferation, Migration, and Invasion by Upregulating HOXA10 in Nasopharyngeal Carcinoma.2022American journal of rhinology & allergy
  6. Let-7i-5p promotes a malignant phenotype in nasopharyngeal carcinoma via inhibiting tumor-suppressive autophagy.2022Cancer letters
  7. Key genes affecting the progression of nasopharyngeal carcinoma identified by RNA-sequencing and bioinformatic analysis.2021AgingFree full text
  8. Continuous quality improvement of nutrition management during radiotherapy in patients with nasopharyngeal carcinoma.2021Nursing openFree full text
More papers found outside PubMed (not counted)13
  1. Salivary metabolomic profiling reveals dynamic metabolic adaptations in nasopharyngeal carcinoma (NPC) patients during radiotherapy2025International Journal of Radiation Researcharticle
  2. Prediction of Parotid Gland Changes in Radiation-Induced Oral Mucositis of Nasopharyngeal Carcinoma Based on Metabolism-Imaging Bimodal Omics2024International Journal of Radiation Oncology*Biology*Physicsarticle
  3. Additional file 1 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  4. Additional file 2 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  5. Additional file 3 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  6. Additional file 4 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  7. Additional file 5 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  8. Additional file 6 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  9. Additional file 7 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  10. Advances of radiotherapy combined with targeted therapy for nasopharyngeal carcinoma2023Radiation Medicine and Protectionarticle
  11. Efficacy and safety of penpulimab-containing regimens for advanced malignant solid tumors that have failed immunotherapy: A real-world study.2023Journal of Clinical Oncologyconference-abstract
  12. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figsharedataset
  13. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 22 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
22
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 6620222023: 3320232024: 5520242025: 772025

3 hospitals in Suzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomicsImaging & AIImmunotherapy
Departments in papersRadiation oncologyMedical oncologyGastroenterology / hepatologyRadiology / nuclear medicine
Papers it led22
  1. RRP9 Promotes Esophageal Squamous Cell Carcinoma Progression through E2F1 Transcriptional Regulation of CDK1.2025Advanced biologyFree full text
  2. Organoid-based two-step drug screening for rapid identification of chemotherapy-resistant oesophageal squamous cell carcinoma and alternative therapies.2025Clinical and translational medicineFree full text
  3. Correlation of immune cell subsets in the tumor microenvironment and peripheral blood with immunotherapy response in esophageal squamous cell carcinoma.2025Frontiers in immunologyFree full text
  4. Decursin Suppresses Esophageal Squamous Cell Carcinoma Progression via Orchestrated Cell Cycle Deceleration, Apoptotic Activation, and Oncoprotein Degradation.2025International journal of molecular sciencesFree full text
  5. A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy with or witho2025Journal of translational medicineFree full text
  6. Improved circulating tumor DNA identification for detection of esophageal squamous cell carcinoma by enzymatic methyl sequencing and hybrid neural network.2025Scientific reportsFree full text
  7. Explainable semi-supervised model for predicting invasion depth of esophageal squamous cell carcinoma based on the IPCL and AVA patterns.2025Scientific reportsFree full text
  8. Diagnostic Efficacy of Type B Vessels in the Japan Esophageal Society Classification for the Depth of Invasion of Superficial Esophageal Squamous Cell Carcinoma.2024Annali italiani di chirurgia
  9. Integrating 18F-FDG PET/CT radiomics and body composition for enhanced prognostic assessment in patients with esophageal cancer.2024BMC cancerFree full text
  10. First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial.2024Cancer immunology, immunotherapy : CIIFree full text
  11. Spatial transcriptome profiling identifies DTX3L and BST2 as key biomarkers in esophageal squamous cell carcinoma tumorigenesis.2024Genome medicineFree full text
  12. A prognostic nomogram for T3N0M0 esophageal squamous cell carcinoma patients undergoing radical surgery based on computed tomography radiomics and inflammatory nutritional biomarkers.2024Journal of applied clinical medical physicsFree full text
  13. RGS16 regulates Hippo-YAP activity to promote esophageal cancer cell proliferation and migration.2023Biochemical and biophysical research communications
  14. Multi-omics analyses reveal spatial heterogeneity in primary and metastatic oesophageal squamous cell carcinoma.2023Clinical and translational medicineFree full text
  15. Peripheral Blood Markers Predictive of Progression-Free Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With PD-1 Inhibitors Plus Chemotherapy as First-Line Therapy.2023Nutrition and cancer
  16. Sesamin exerts anti-tumor activity in esophageal squamous cell carcinoma via inhibition of TRIM44 and NF-κB signaling.2022Chemical biology & drug design
  17. Verbascoside represses malignant phenotypes of esophageal squamous cell carcinoma cells by inhibiting CDC42 via the HMGB1/RAGE axis.2022Human & experimental toxicology
  18. microRNA-497-mediated Smurf2/YY1/HIF2α axis in tumor growth and metastasis of esophageal squamous cell carcinoma.2022Journal of biochemical and molecular toxicology
  19. Esophageal carcinosarcoma comprising undifferentiated pleomorphic sarcoma and squamous cell carcinoma: a case report.2022Journal of cardiothoracic surgeryFree full text
  20. Overcoming radio-resistance in esophageal squamous cell carcinoma via hypermethylation of PIK3C3 promoter region mediated by KDM5B loss.2022Journal of radiation researchFree full text
  21. Can Lymphovascular Invasion be Predicted by Preoperative Contrast-Enhanced CT in Esophageal Squamous Cell Carcinoma?2022Technology in cancer research & treatmentFree full text
  22. Mechanism and Role of the Neuropeptide LGI1 Receptor ADAM23 in Regulating Biomarkers of Ferroptosis and Progression of Esophageal Cancer.2021Disease markersFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal FloraStatus unknownNCT05199649Lead sponsorN/AStart 2021-12
  2. Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell CarcinomaStatus unknownNCT05174325Lead sponsorPhase 2Start 2020-12
  3. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT01232374Study sitePhase 2Start 2010-09
More papers found outside PubMed (not counted)18
  1. A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy with or witho2025Figsharesupplementary-materials
  2. Abstract 1945: High-sensitive gastrointestinal cancers early detection by cell-free DNA targeted methylation sequencing with an innovative modeling approach2025Cancer Researchconference-abstract
  3. Additional file 1 of A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradio2025Figsharearticle
  4. ESCC-eCura: A Novel Scoring System to Assess Curability after Endoscopic Submucosal Dissection for Superficial Esophageal Squamous Cell Carcinoma2025SSRN Electronic Journalpreprint
  5. Kurarinone's synergistic target space and therapeutic promise for esophageal squamous cell carcinoma are revealed by systems pharmacology2025Research Squarepreprint
  6. Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial2025International Journal of Radiation Oncology*Biology*Physicsarticle
  7. Regulation and function of the RSK family in colorectal cancer2024Journal of Cancer Metastasis and Treatmentarticle
  8. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figsharedataset
  9. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  10. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  11. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  12. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  13. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  14. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset
  15. Exosomal miR-29b-3p derived from cancer- associated fibroblasts contributes to esophageal squamous cell carcinoma cell progression by NAA60 hypomethylation2022Research Squarepreprint
  16. Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  17. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset
  18. The preliminary efficacy and safety of KN046 plus concurrent chemoradiation therapy in recurrent and metastatic esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 73 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
73
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 151520212022: 161620222023: 111120232024: 131320242025: 17172025

2 hospitals in Suzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging, AI & early detectionLocal treatment (ablation, TACE, HAIC)Recurrence & prognosis
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Medical oncology
Papers it led73
  1. Gd-EOB-DTPA-enhanced MRI radiomics and deep learning models for predicting the pathological differentiation degree in hepatocellular carcinoma.2026European journal of radiology
  2. Functional regulatory roles of HNF1B in promoting cell proliferation, migration, invasion and fate decision of hepatocellular carcinoma.2025BMC cancerFree full text
  3. Hepatocellular carcinoma (HCC) and focal nodular hyperplasia (FNH) showing iso- or hyperintensity in the hepatobiliary phase: differentiation using Gd-EOB-DTPA enhanced MRI radiomics and deep learning features.2025BMC medical imagingFree full text
  4. A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  5. Construction of an Oxidative Stress Risk Model to Analyze the Correlation Between Liver Cancer and Tumor Immunity.2025Current cancer drug targets
  6. Clinical characteristics and risk factors of hepatocellular carcinoma development in Budd-Chiari syndrome patients after endovascular treatment.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  7. FBXO42 promotes hepatocellular carcinoma progression via mediating p57Kip2 ubiquitination and degradation.2025European journal of medical researchFree full text
  8. CircBRWD1 promotes hepatitis B virus replication and hepatocellular carcinoma progression by regulating the miR-513a-5p/TNPO1 axis.2025Experimental cell research
  9. Survival benefits of different immunotherapies for hepatocellular carcinoma: a meta-analysis highlighting age, gender, etiology, and tumor burden.2025Frontiers in immunologyFree full text
  10. KRT80 in hepatocellular carcinoma plays oncogenic role via epithelial-mesenchymal transition and PI3K/AKT pathway.2025IUBMB life
  11. Prexasertib exerts a synergistic effect on the antitumor activity of Lenvatinib through ALOX15-mediated ferroptosis in hepatocellular carcinoma.2025International immunopharmacology
  12. Safety and efficacy of TACE combined with immune checkpoint inhibitors plus molecular targeted therapies in older adults with unresectable hepatocellular carcinoma.2025Journal of cancer research and clinical oncologyFree full text
  13. Transarterial chemoembolization combined with percutaneous ethanol injection for the treatment of hepatocellular carcinoma at high-risk areas.2025Journal of cancer research and therapeutics
  14. Heterogeneity Habitats -Derived Radiomics of Gd-EOB-DTPA Enhanced MRI for Predicting Proliferation of Hepatocellular Carcinoma.2025Journal of computer assisted tomographyFree full text
  15. Deep Learning Radiopathomics Models Based on Contrast-enhanced MRI and Pathologic Imaging for Predicting Vessels Encapsulating Tumor Clusters and Prognosis in Hepatocellular Carcinoma.2025Radiology. Imaging cancerFree full text
  16. PARK7-driven IGF2BP3-K76 lactylation mediates ferroptosis and HAIC resistance in hepatocellular carcinoma.2025Redox biologyFree full text
  17. Development and validation of a prealbumin-bilirubin model for prognostic prediction in intermediate hepatocellular carcinoma undergoing transarterial chemoembolization.2025Scientific reportsFree full text
  18. Efficacy and safety of hepatic arterial infusion chemotherapy followed by transarterial embolization for hepatocellular carcinoma.2025Tumori
  19. Emergent TIPS for acute gastroesophageal variceal bleeding in cirrhotic patients with hepatocellular carcinoma.2024Abdominal radiology (New York)
  20. Tim-1-mediated extracellular matrix promotes the development of hepatocellular carcinoma.2024Acta biochimica et biophysica SinicaFree full text
  21. Identification and evaluation of plasma exosome RNA biomarkers for non-invasive diagnosis of hepatocellular carcinoma using RNA-seq.2024BMC cancerFree full text
  22. Gd-EOB-DTPA enhanced MRI nomogram model to differentiate hepatocellular carcinoma and focal nodular hyperplasia both showing iso- or hyperintensity in the hepatobiliary phase.2024BMC medical imagingFree full text
  23. miR-29a-SIRT1-Wnt/β-Catenin Axis Regulates Tumor Progression and Survival in Hepatocellular Carcinoma.2024Biochemical genetics
  24. Long Non-coding RNA LINC00342 Promotes the Proliferation, Invasion, and Migration of Primary Hepatocellular Carcinoma Cells by Regulating the Expression of miRNA-19a-3p, miRNA-545-5p, and miRNA-203a-3p.2024Biochemical genetics
  25. Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8+T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model.2024Cardiovascular and interventional radiology
  26. The Incidences and Related CT Features of Vascular Lake Phenomenon on Angiography Before Chemoembolization.2024Cardiovascular and interventional radiology
  27. Transarterial chemoembolization refractoriness in hepatocellular carcinoma: Chinese College of Interventionalists definition and consensus statement.2024Chinese medical journalFree full text
  28. Radiomic Analysis of Contrast-Enhanced CT Predicts Glypican 3-Positive Hepatocellular Carcinoma.2024Current medical imaging
  29. Cryoablation combined with dual immune checkpoint blockade enhances antitumor efficacy in hepatocellular carcinoma model mice.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  30. Which risk model can better predict hepatocellular carcinoma in hepatitis B patients with an antiviral treatment duration of over 1 year?2024Journal of hepatology
  31. Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α.2024Pakistan journal of pharmaceutical sciences
  32. Machine learning based on gadoxetic acid-enhanced MRI for differentiating atypical intrahepatic mass-forming cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.2023Abdominal radiology (New York)
  33. Circular RNA hsa_circ_0005239 contributes to hepatocellular carcinoma cell migration, invasion, and angiogenesis by targeting the miR-34a-5p/PD-L1 axis.2023Cell biology international
  34. Cuproptosis-related lncRNAs predict the prognosis and immune response in hepatocellular carcinoma.2023Clinical and experimental medicine
  35. The Role of Oxidative Stress in the Development and Therapeutic Intervention of Hepatocellular Carcinoma.2023Current cancer drug targets
  36. Letter re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.2023European journal of cancer (Oxford, England : 1990)
  37. Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study.2023Frontiers in immunologyFree full text
  38. LncRNA NUTM2A-AS1 aggravates the progression of hepatocellular carcinoma by activating the miR-186-5p/KLF7-mediated Wnt/beta-catenin pathway.2023Human cell
  39. Nomogram Estimating Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma From Preoperative Gadoxetate Disodium-Enhanced MRI.2023Journal of magnetic resonance imaging : JMRI
  40. Preoperative Diagnosis of Dual-Phenotype Hepatocellular Carcinoma Using Enhanced MRI Radiomics Models.2023Journal of magnetic resonance imaging : JMRIRCT
  41. LINC00106/RPS19BP1/p53 axis promotes the proliferation and migration of human prostate cancer cells.2023PeerJFree full text
  42. Global profiling of protein lysine lactylation and potential target modified protein analysis in hepatocellular carcinoma.2023Proteomics
  43. Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma.2022Briefings in bioinformatics
  44. hsa_circ_0003410 promotes hepatocellular carcinoma progression by increasing the ratio of M2/M1 macrophages through the miR-139-3p/CCL5 axis.2022Cancer scienceFree full text
  45. Preoperative CECT-based Radiomic Signature for Predicting the Response of Transarterial Chemoembolization (TACE) Therapy in Hepatocellular Carcinoma.2022Cardiovascular and interventional radiology
  46. LINC02535/miR-30a-5p/GALNT3 axis contributes to lung adenocarcinoma progression via the NF- κ B signaling pathway.2022Cell cycle (Georgetown, Tex.)Free full text
  47. Gd-EOB-DTPA-enhanced MRI radiomics to predict vessels encapsulating tumor clusters (VETC) and patient prognosis in hepatocellular carcinoma.2022European radiology
  48. Hypothyroidism has a protective causal association with hepatocellular carcinoma: A two-sample Mendelian randomization study.2022Frontiers in endocrinologyFree full text
  49. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  50. Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response.2022Frontiers in immunologyFree full text
  51. Comprehensive Analysis on the Specific Role and Function of Mitochondrial Inner Membrane Protein MPV17 in Liver Hepatocellular Carcinoma.2022Genetics researchFree full text
  52. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty live2022Hepatobiliary & pancreatic diseases international : HBPD INT
  53. Re: "Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis".2022Journal of vascular and interventional radiology : JVIR
  54. Insights into the Allosteric Effect of SENP1 Q597A Mutation on the Hydrolytic Reaction of SUMO1 via an Integrated Computational Study.2022Molecules (Basel, Switzerland)Free full text
  55. Cytotoxic and anti-tumor effects of 3,4-seco-lupane triterpenoids from the leaves of Eleutherococcus sessiliflorus against hepatocellular carcinoma.2022Natural product research
  56. Immune suppressive function of IL-1α release in the tumor microenvironment regulated by calpain 1.2022OncoimmunologyFree full text
  57. Activating transcription factor 2 promotes the progression of hepatocellular carcinoma by inducing the activation of the WHSC1-mediated TOP2A/PI3K/AKT axis.2022The Kaohsiung journal of medical sciencesFree full text
  58. Lysine demethylase 5C epigenetically reduces transcription of ITIH1 that results in augmented progression of liver hepatocellular carcinoma.2022The Kaohsiung journal of medical sciencesFree full text
  59. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.2021AJR. American journal of roentgenology
  60. LncRNA PCGEM1 mediates oxaliplatin resistance in hepatocellular carcinoma via miR-129-5p/ETV1 axis in vitro.2021Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  61. RUFY3 promotes the progression of hepatocellular carcinoma through activating NF-κB-mediated epithelial-mesenchymal transition.2021AgingFree full text
  62. Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma.2021BMC medical imagingFree full text
  63. MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling.2021Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicasFree full text
  64. Integrated I-125 Seed Implantation Combined with Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombus.2021Cardiovascular and interventional radiology
  65. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.2021Cardiovascular and interventional radiology
  66. CT-based radiomics model to distinguish necrotic hepatocellular carcinoma from pyogenic liver abscess.2021Clinical radiology
  67. Silencing PFKP restrains the stemness of hepatocellular carcinoma cells.2021Experimental cell research
  68. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.2021Journal of cancer research and therapeutics
  69. ceRNA network development and tumor-infiltrating immune cell analysis in hepatocellular carcinoma.2021Medical oncology (Northwood, London, England)
  70. miR-760 mediated the proliferation and metastasis of hepatocellular carcinoma cells by regulating HMGA2.2021Pathology, research and practice
  71. cFUT8 promotes liver cancer progression by miR-548c/FUT8 axis.2021Signal transduction and targeted therapyFree full text
  72. Imaging features based on Gd-EOB-DTPA-enhanced MRI for predicting vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma.2021The British journal of radiologyFree full text
  73. Correlation of radiomic features on dynamic contrast-enhanced magnetic resonance with microvessel density in hepatocellular carcinoma based on different models.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)7
  1. [Diagnosis and differential diagnosis of small hepatocellular carcinoma in the context of cirrhosis].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Efficacy and safety of transarterial chemoembolization combined with sintilimab and bevacizumab biosimilar for unresectable hepatocellular carcinoma].2025Zhonghua nei ke za zhi
  3. [Diagnostic value of Gd-EOB-DTPA-enhanced MRI radiomics models for dual-phenotype hepatocellular carcinoma].2024Zhonghua yi xue za zhi
  4. [Construction of a prognostic model for hepatocellular carcinoma based on pyroptosis-related genes].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  5. [The application value of Gd-EOB-DTPA enhanced MRI based radiomics in the differential diagnosis of iso-or hyperintensity HCC and focal nodular hyperplasia in hepatobiliary phase].2023Zhonghua yi xue za zhiRCT
  6. [The prediction value of enhanced magnetic resonance imaging nomogram model for dual phenotype hepatocellular carcinoma].2022Zhonghua yi xue za zhiRCT
  7. [Value of the application of enhanced CT radiomics and machine learning in preoperative prediction of microvascular invasion in hepatocellular carcinoma].2021Zhonghua yi xue za zhiRCT
All its trials on ClinicalTrials.gov, any status6
  1. Evaluate the Effect of Tirazamine on Primary Liver Cancer.TerminatedNCT06848556Study sitePhase 1/Phase 2Start 2021-05
  2. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  3. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  4. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  5. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  6. Efficacy Study of TACE to Treat Hepatocellular Carcinoma After OperationStatus unknownNCT02631499Study sitePhase 4Start 2015-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 90 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.9%.

Papers led
90
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 101020212022: 222220222023: 242420232024: 131320242025: 17172025

3 hospitals in Suzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging
    Phase
    Not given
    Started
    2026-05
    Registry
    NCT07551466

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  2. Recruiting
    Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT07012447

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  3. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  4. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

  5. Not yet recruiting
    Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07902596

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 6 listed hospitals as study sitesNanjing, Qingdao, Shanghai, Shijiazhuang, Suzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseEarly detection & endoscopyImaging & AI
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRheumatology & immunologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led90
  1. Integrating narrative therapy and sleep intervention to enhance recovery, nutritional reconstitution, and 24-month survival following curative gastrectomy: a randomized controlled trial.2026Journal of cancer survivorship : research and practiceRCT
  2. Psychosocial intervention to improve sleep, psychological adjustment, and quality of life in gastric cancer patients undergoing gastrectomy: a randomized controlled trial.2026Journal of cancer survivorship : research and practiceRCT
  3. Combined Effects of Psychological Intervention and Enhanced Nutritional Support on Postoperative Recovery in Gastric Cancer Patients.2026Nutrition and cancerRCT
  4. Combined sleep intervention and nutritional support to enhance postoperative recovery in gastric cancer: a prospective randomized controlled trial.2026Surgical endoscopyRCT
  5. Targeting PTBP3-Mediated Alternative Splicing of COX11 Induces Cuproptosis for Inhibiting Gastric Cancer Peritoneal Metastasis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  6. Virtual NBI image synthesis using stable diffusion for enhanced recognition of early gastric cancer: a technical validation study.2025Annals of medicineFree full text
  7. Artificial intelligence-assisted diagnosis of early gastric cancer: present practice and future prospects.2025Annals of medicineFree full text
  8. Psychological Interventions and Sleep Improvement for Patients with Gastric Cancer: Effects on Immune Function, Inflammation, and Tumor Progression-A Randomized Controlled Trial.2025Annals of surgical oncologyRCT
  9. The LINC01094/miR-545-3p/SLC7A11 Signaling Axis Promotes the Development of Gastric Cancer by Regulating Cell Growth and Ferroptosis.2025Biochemical geneticsFree full text
  10. Artificial intelligence-driven microRNA signature for early detection of gastric cancer: discovery and clinical functional exploration.2025British journal of cancerFree full text
  11. JMJD3 upregulates ALOX5 to drive malignancy and concomitant ferroptosis sensitivity in gastric cancer.2025Cell death & diseaseFree full text
  12. Tumor exosomal circPTBP3 drives gastric cancer peritoneal metastasis via mesothelial-mesenchymal transition.2025Cell death & diseaseFree full text
  13. CST1 promoted gastric cancer development by activating the AKT pathway.2025Clinics (Sao Paulo, Brazil)Free full text
  14. Enhancing short-term recovery after gastric cancer surgery: an information-motivation-behavioral skills (IMB) model with nutritional support.2025Future oncology (London, England)RCTFree full text
  15. HIF-1α Promotes the Confined Migration of Gastric Cancer Cells by Modulating Phosphatidylcholine Metabolism.2025Journal of cellular and molecular medicineFree full text
  16. N‑methyladenosine reader YTHDF2‑mediated AC026691.1 degradation promotes gastric cancer cell proliferation, migration and M2 macrophage polarization.2025Molecular medicine reportsFree full text
  17. CBX4 Drives Gastric Cancer Progression by Activating β-Catenin Signaling.2025Oncology researchFree full text
  18. FBLN2 inhibits gastric cancer proliferation and metastasis via the TGFβ/TGIF2 pathway.2025Pathology, research and practice
  19. Coprevalence of modifiable gastric cancer risk factors and gastric health among Chinese high-risk groups.2025Scientific reportsFree full text
  20. Identification of a LncRNA based CeRNA network signature to establish a prognostic model and explore potential therapeutic targets in gastric cancer.2025Scientific reportsFree full text
  21. B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy.2025Technology in cancer research & treatmentFree full text
  22. Predicting esophagojejunal anastomotic leakage in gastric cancer patients after total gastrectomy: Development and assessment of a new predictive nomogram.2024Asian journal of surgery
  23. Glycolysis-related genes predict prognosis and indicate immune microenvironment features in gastric cancer.2024BMC cancerFree full text
  24. Differentially expressed microRNA in prognosis of gastric cancer with Lauren classification.2024Cancer biomarkers : section A of Disease markersFree full text
  25. Exosome-derived proteins in gastric cancer progression, drug resistance, and immune response.2024Cellular & molecular biology lettersFree full text
  26. TREM1 facilitates the development of gastric cancer through regulating neutrophil extracellular traps-mediated macrophage polarization.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  27. From mitochondria to tumor suppression: ACAT1's crucial role in gastric cancer.2024Frontiers in immunologyFree full text
  28. ITGBL1 promotes anoikis resistance and metastasis in human gastric cancer via the AKT/FBLN2 axis.2024Journal of cellular and molecular medicineFree full text
  29. FOLR2+ macrophage depletion from intestinal metaplasia to early gastric cancer: single-cell sequencing insight into gastric cancer progression.2024Journal of experimental & clinical cancer research : CRFree full text
  30. BUB1 potentiates gastric cancer proliferation and metastasis by activating TRAF6/NF-κB/FGF18 through m6A modification.2024Life sciences
  31. Construction of a TAN-associated risk score model with integrated multi-omics data analysis and clinical validation in gastric cancer.2024Life sciences
  32. Cancer-associated fibroblasts promote proliferation, angiogenesis, metastasis and immunosuppression in gastric cancer.2024Matrix biology : journal of the International Society for Matrix Biology
  33. ARTN-GFRA3 axis induces epithelial-mesenchymal transition phenotypes, migration, and invasion of gastric cancer cells via KRAS signaling.2024Neoplasma
  34. Comparison analysis of two different types of endoscopic resection procedures in small gastric subepithelial tumours originating frommuscularis propria.2024Scandinavian journal of gastroenterology
  35. PRSS2 regulates EMT and metastasis via MMP-9 in gastric cancer.2023Acta histochemica
  36. Identification and validation of crucial lnc-TRIM28-14 and hub genes promoting gastric cancer peritoneal metastasis.2023BMC cancerFree full text
  37. The combination of preoperative fibrinogen-to-albumin ratio and postoperative TNM stage (FAR-TNM) predicts the survival in gastric cancer patients after gastrectomy.2023Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  38. Feasibility evaluation of hsa_circ_0005480 as an auxiliary diagnostic and prognostic indicator for gastric cancer.2023Biomarkers in medicine
  39. Loss of NDUFS1 promotes gastric cancer progression by activating the mitochondrial ROS-HIF1α-FBLN5 signaling pathway.2023British journal of cancerFree full text
  40. Over-Expression of ARID3B Suppresses Tumor Progression and Predicts Better Prognosis in Patients With Gastric Cancer.2023Cancer control : journal of the Moffitt Cancer CenterFree full text
  41. Gastric cancer derived exosomal THBS1 enhanced Vγ9Vδ2 T-cell function through activating RIG-I-like receptor signaling pathway in a N6-methyladenosine methylation dependent manner.2023Cancer letters
  42. Hsa-circ-0052001 promotes gastric cancer cell proliferation and invasion via the MAPK pathway.2023Cancer medicineFree full text
  43. B7-H3 confers stemness characteristics to gastric cancer cells by promoting glutathione metabolism through AKT/pAKT/Nrf2 pathway.2023Chinese medical journalFree full text
  44. Identification of gastric signet ring cell carcinoma based on endoscopic images using few-shot learning.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  45. GADD45B regulates the carcinogenesis process of chronic atrophic gastritis and the metabolic pathways of gastric cancer.2023Frontiers in endocrinologyFree full text
  46. Clinical significance of CD155 expression and correlation with cellular components of tumor microenvironment in gastric adenocarcinoma.2023Frontiers in immunologyFree full text
  47. Knockdown of LINC01087 inhibits gastric cancer malignant behavior by regulating the miR-135a-5p/CAAP1 axis.2023Functional & integrative genomics
  48. LncRNA RUNX1-IT1 is downregulated in gastric cancer and suppresses the maturation of miR-20a by binding to its precursor.2023Histology and histopathology
  49. miRNA-223-3p regulates ECT2 to promote proliferation, invasion, and metastasis of gastric cancer through the Wnt/β-catenin signaling pathway.2023Journal of cancer research and clinical oncologyFree full text
  50. B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy.2023Journal of cancer research and clinical oncologyFree full text
  51. Integrated multi-dimensional analysis highlights DHCR7 mutations involving in cholesterol biosynthesis and contributing therapy of gastric cancer.2023Journal of experimental & clinical cancer research : CRFree full text
  52. MiR-200/183 family-mediated module biomarker for gastric cancer progression: an AI-assisted bioinformatics method with experimental functional survey.2023Journal of translational medicineFree full text
  53. Expression and clinical significance of PD-L1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment.2023MedicineFree full text
  54. An evaluation of the use of double-curved endoscopes for gastric gastrointestinal stromal tumors.2023Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  55. CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1.2023OncogeneFree full text
  56. TRIM69 suppressed the anoikis resistance and metastasis of gastric cancer through ubiquitin‒proteasome-mediated degradation of PRKCD.2023Oncogene
  57. Learning curve for endoscopic resection of gastric gastrointestinal stromal tumors: a single-center experience.2023Revista espanola de enfermedades digestivas
  58. Risk factors for conversion from endoscopic resection to laparoscopic resection for gastric gastrointestinal stromal tumors.2023The Journal of international medical researchFree full text
  59. The added value of radiomics from dual-energy spectral CT derived iodine-based material decomposition images in predicting histological grade of gastric cancer.2022BMC medical imagingFree full text
  60. Activation of WNT/CTNNB1/TCF7L2 in Epstein-Barr virus-positive gastric cancer regulates epithelial mesenchymal transition.2022Biochemical and biophysical research communications
  61. Circular RNA circ_0001017 Sensitizes Cisplatin-Resistant Gastric Cancer Cells to Chemotherapy by the miR-543/PHLPP2 Axis.2022Biochemical genetics
  62. MicroRNA-642b-3p functions as an oncomiR in gastric cancer by down-regulating the CUB and sushi multiple domains protein 1/smad axis.2022BioengineeredFree full text
  63. Risk Factors and Timing of Additional Surgery after Noncurative ESD for Early Gastric Cancer.2022Canadian journal of gastroenterology & hepatologyFree full text
  64. Evaluation of the role of soluble B7-H3 in association with membrane B7-H3 expression in gastric adenocarcinoma.2022Cancer biomarkers : section A of Disease markersFree full text
  65. Gastric cancer-derived exosomal miR-135b-5p impairs the function of Vγ9Vδ2 T cells by targeting specificity protein 1.2022Cancer immunology, immunotherapy : CIIFree full text
  66. Cancer-associated fibroblast-released extracellular vesicles carrying miR-199a-5p induces the progression of​ gastric cancer through regulation of FKBP5-mediated AKT1/mTORC1 signaling pathway.2022Cell cycle (Georgetown, Tex.)Free full text
  67. Adenosine triphosphate-based tumor chemosensitivity assay may predict the clinical outcomes of gastric cancer patients receiving taxane-based post-operative adjuvant chemotherapy.2022Chinese medical journalFree full text
  68. Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients.2022Clinics and research in hepatology and gastroenterology
  69. Steroid Receptor Coactivator-1 (SRC-1) Promoted Cell Metastasis of Gastric Cancer via VEGFC Activator by NF-κB.2022Critical reviews in eukaryotic gene expression
  70. miR-622 Counteracts the NUAK1-Induced Gastric Cancer Cell Proliferation and the Antioxidative Stress.2022Disease markersFree full text
  71. Roux-en-Y reconstruction alleviates radical gastrectomy-induced colitis via down-regulation of the butyrate/NLRP3 signaling pathway.2022EBioMedicineFree full text
  72. The Deubiquitinating Enzyme USP4 Functions as an Oncoprotein in Gastric Cancer and Mediates NF-κB Signaling by Regulating PRL-3 Expression.2022Frontiers in bioscience (Landmark edition)
  73. A vasculogenic mimicry prognostic signature associated with immune signature in human gastric cancer.2022Frontiers in immunologyFree full text
  74. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.2022International immunopharmacology
  75. Diagnosis value of miR-181, miR-652, and CA72-4 for gastric cancer.2022Journal of clinical laboratory analysisFree full text
  76. Establishment of a Monoclonal Antibody-Based Enzyme-Linked Immunosorbent Assay to Measure Soluble B7-H5 in Patients with Cancer.2022Journal of immunology researchFree full text
  77. Clinical Value of Pepsinogen in the Screening, Prevention, and Diagnosis of Gastric Cancer.2022Laboratory medicine
  78. Billroth II anastomosis maintains SMI and BMI better than Roux-en-Y anastomosis following totally laparoscopic distal gastrectomy: a propensity score-matched study.2022Langenbeck's archives of surgery
  79. PRKAA1, stabilized by FTO in an m6A-YTHDF2-dependent manner, promotes cell proliferation and glycolysis of gastric cancer by regulating the redox balance.2022Neoplasma
  80. LINC00922 acts as a novel oncogene in gastric cancer.2022World journal of surgical oncologyFree full text
  81. Evaluating health-related quality of life in gastric cancer patients in Suzhou, China.2021Annals of palliative medicine
  82. Chinese and global burdens of gastric cancer from 1990 to 2019.2021Cancer medicineFree full text
  83. H19 promotes aerobic glycolysis, proliferation, and immune escape of gastric cancer cells through the microRNA-519d-3p/lactate dehydrogenase A axis.2021Cancer scienceFree full text
  84. Application of Hemocoagulase Bothrops Atrox in the submucosal injection for endoscopic submucosal dissection: a preliminary trial.2021European journal of gastroenterology & hepatologyRCTFree full text
  85. ONECUT2 which is targeted by hsa-miR-15a-5p enhances stemness maintenance of gastric cancer stem cells.2021Experimental biology and medicine (Maywood, N.J.)Free full text
  86. LncRNA-HEIH is a Novel Diagnostic and Predictive Biomarker in Gastric Cancer.2021Genetic testing and molecular biomarkers
  87. LINC02535 promotes cell growth in poorly differentiated gastric cancer.2021Journal of clinical laboratory analysisFree full text
  88. Circular RNA circ_HN1 facilitates gastric cancer progression through modulation of the miR-302b-3p/ROCK2 axis.2021Molecular and cellular biochemistry
  89. Circular RNA hsa_circ_0072309 inhibits the proliferation, invasion and migration of gastric cancer cells via inhibition of PI3K/AKT signaling by activating PPARγ/PTEN signaling.2021Molecular medicine reportsFree full text
  90. SIRT5 regulates autophagy and apoptosis in gastric cancer cells.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)5
  1. [Risk factors for complications of endoscopic full-thickness resection of upper gastrointestinal submucosal tumors].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Study of immunophenotypic characteristics, clinicopathological parameters and prognosis in gastric cancer microenvironment].2023Zhonghua yi xue za zhi
  3. [Analysis of efficacy and safety of a new endoscopic anastomosis clip in the treatment of defects after endoscopic full-thickness resection].2023Zhonghua yi xue za zhi
  4. [Gastric adenocarcinoma with enteroblastic differentiation combined with liver metastasis: report of a case].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  5. [Application of fecal DNA methylation biomarkers detection in gastric cancer screening].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status11
  1. AI Model for Early Gastric Cancer Diagnosis Using Endoscopic ImagingRecruitingNCT07551466Lead sponsorStart 2026-05
  2. Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid MutationsRecruitingNCT07012447Lead (inferred)Phase 2Start 2025-04
  3. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  4. Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ AdenocarcinomaNot yet recruitingNCT07902596Study siteStart 2026-10
  5. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  6. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  7. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in ChinaCompletedNCT06585501Study siteStart 2024-08
  8. Phase IIT Trial of SNA014Status unknownNCT06646783Study siteEarly phase 1Start 2024-10
  9. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  10. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center StudyStatus unknownNCT03121729Study siteN/AStart 2017-06
  11. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

3 hospitals in Suzhou for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 2 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Suzhou for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

16 hospitals in Suzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led4
  1. A microsphere-vesicle hybrid system for tumor treatment through enhancement of innate and adaptive immune responses.2026Biomaterials
  2. GD2-mediated impairment of macrophage phagocytosis drives pulmonary metastasis in osteosarcoma.2025Theranostics
  3. Targeting POLRMT by a first-in-class inhibitor IMT1 inhibits osteosarcoma cell growth in vitro and in vivo.2024Cell death & disease
  4. Bioinformatics analysis of key pathways and genes in osteosarcoma development.2023Panminerva medica
Earlier papers (2016–2020)13
  1. TRIM58 Interacts with Pyruvate Kinase M2 to Inhibit Tumorigenicity in Human Osteosarcoma Cells.2020BioMed research international
  2. LINC00612 functions as a ceRNA for miR-214-5p to promote the proliferation and invasion of osteosarcoma in vitro and in vivo.2020Experimental cell research
  3. The Effects of Interleukin-33 (IL-33) on Osteosarcoma Cell Viability, Apoptosis, and Epithelial-Mesenchymal Transition are Mediated Through the PI3K/AKT Pathway.2020Medical science monitor : international medical journal of experimental and clinical research
  4. Long non-coding RNA Taurine upregulated gene 1 promotes osteosarcoma cell metastasis by mediating HIF-1α via miR-143-5p.2019Cell death & disease
  5. Feedback modulation of endothelial cells promotes epithelial-mesenchymal transition and metastasis of osteosarcoma cells by Von Willebrand Factor release.2019Journal of cellular biochemistry
  6. MicroRNA-221 regulates osteosarcoma cell proliferation, apoptosis, migration, and invasion by targeting CDKN1B/p27.2019Journal of cellular biochemistry
  7. NEAT1 induces osteosarcoma development by modulating the miR-339-5p/TGF-β1 pathway.2019Journal of cellular physiology
  8. Transcription factor CEBPB inhibits the proliferation of osteosarcoma by regulating downstream target gene CLEC5A.2019Journal of clinical laboratory analysis
  9. MiR-183 inhibits osteosarcoma cell growth and invasion by regulating LRP6-Wnt/β-catenin signaling pathway.2018Biochemical and biophysical research communications
  10. von Willebrand factor rescued by miR-24 inhibition facilitates the proliferation and migration of osteosarcoma cells in vitro.2018Bioscience reports
  11. DownRegulated SOX4 Expression Suppresses Cell Proliferation, Migration, and Induces Apoptosis in Osteosarcoma In Vitro and In Vivo.2018Calcified tissue international
  12. Mechanisms of oxidative stress, apoptosis, and autophagy involved in graphene oxide nanomaterial anti-osteosarcoma effect.2018International journal of nanomedicine
  13. The lncRNA HNF1A-AS1 is a negative prognostic factor and promotes tumorigenesis in osteosarcoma.2017Journal of cellular and molecular medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 6 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.1%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 3320232024: 1120242025: 002025

6 hospitals in Suzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)
Papers it led6
  1. Comparison analysis of two different types of endoscopic resection procedures in small gastric subepithelial tumours originating frommuscularis propria.2024Scandinavian journal of gastroenterology
  2. An evaluation of the use of double-curved endoscopes for gastric gastrointestinal stromal tumors.2023Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  3. Learning curve for endoscopic resection of gastric gastrointestinal stromal tumors: a single-center experience.2023Revista espanola de enfermedades digestivas
  4. Risk factors for conversion from endoscopic resection to laparoscopic resection for gastric gastrointestinal stromal tumors.2023The Journal of international medical researchFree full text
  5. The synergistic therapeutic effect of imatinib and protein kinase CK2 Inhibition correlates with PI3K-AKT activation in gastrointestinal stromal tumors.2022Clinics and research in hepatology and gastroenterology
  6. Endoscopic submucosal dissection for ultra-low large rectal stromal tumor after preoperative imatinib therapy: A case report and review.2022Journal of digestive diseases
Earlier papers (2016–2020)2
  1. A comparative study of treatment of gastrointestinal stromal tumors with laparoscopic surgery: a retrospective study.2018Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  2. Application of novel endoloops to close the defects resulted from endoscopic full-thickness resection with single-channel gastroscope: a multicenter study.2017Surgical endoscopy

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Suzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 27 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.6%.

Papers led
27
2021–2025
Trials led
20
any status, ClinicalTrials.gov
Open trials led
7
recruiting or about to
Open trials as a site
10
led by another institution
Papers led per year
2021: 6620212022: 2220222023: 7720232024: 5520242025: 772025

2 hospitals in Suzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 17

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
    Phase
    Early phase 1
    Started
    2025-07
    Registry
    NCT06730256

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  2. Recruiting
    Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07652138

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  3. Recruiting
    Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
    Phase
    Phase 4
    Started
    2024-06
    Registry
    NCT06409702

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  4. Recruiting
    Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06682156

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  5. Recruiting
    Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
    Phase
    Phase 1/Phase 2
    Started
    2019-07
    Registry
    NCT04025450

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  6. Recruiting
    Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2016-09
    Registry
    NCT03196414

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  7. Not yet recruiting
    A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
    Phase
    Phase 4
    Started
    2026-07
    Registry
    NCT07709884

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  8. Recruiting
    To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Registry
    NCT07454187

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Suzhou, Xi'an, Zhengzhou

  9. Recruiting
    A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-06
    Registry
    NCT07490613

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou

  10. Recruiting
    Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07529782

    Age Not stated to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Suzhou, Tianjin

  11. Recruiting
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07555938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  12. Recruiting
    A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Registry
    NCT07760454

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Suzhou

  13. Recruiting
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06083207

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou

  14. Recruiting
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06508983

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou

  15. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  16. Recruiting
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05623020

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  17. Recruiting
    A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2021-02
    Registry
    NCT04634552

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Suzhou, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskCAR-T & cell therapyStem cell transplant
Departments in papersRadiology / nuclear medicinePathology / laboratory medicineNeurology
Papers it led27
  1. Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone.2025British journal of haematologyFree full text
  2. Redefining multiple myeloma treatment: Advances, challenges, and future directions in immunotherapy.2025Chinese medical journalFree full text
  3. A rare case of concurrent JAK2V617F-positive essential thrombocythemia, multiple myeloma, and colorectal adenocarcinoma.2025Indian journal of pathology & microbiology
  4. A 2D-STI echocardiographic diagnostic model established for cardiac amyloidosis complicated with multiple myeloma.2025International journal of cardiology
  5. Effect of oral care models on the prevention of oral mucositis induced by high-doses of melphalan in patients undergoing ASCT.2025MedicineFree full text
  6. Application of individualized low-protein diet nursing for managing multiple myeloma patients with renal impairment.2025MedicineFree full text
  7. Landscapes of immunoglobulin heavy-chain gene repertoire and its cytogenetic abnormalities in Chinese patients with multiple myeloma.2025Scientific reportsFree full text
  8. Effective Treatment with Venetoclax and Hypomethylating Agents for the Coexistence of Multiple Myeloma and Acute Myeloid Leukemia: A Case Report and Literature Review.2024Annals of clinical and laboratory science
  9. MRI-based bone marrow radiomics for predicting cytogenetic abnormalities in multiple myeloma.2024Clinical radiology
  10. Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant.2024Leukemia & lymphoma
  11. Quantitative assessment of bone marrow infiltration and characterization of tumor burden using dual-layer spectral CT in patients with multiple myeloma.2024Radiology and oncologyFree full text
  12. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.2024The New England journal of medicineRCT
  13. Autologous stem cell transplantation in multiple myeloma patients with renal impairment.2023Annals of hematology
  14. Discriminating minimal residual disease status in multiple myeloma based on MRI: utility of radiomics and comparison of machine-learning methods.2023Clinical radiology
  15. Increased expression of CEP72 predicts poor prognosis in multiple myeloma.2023International journal of laboratory hematology
  16. Nursing care of patients with relapsed and refractory multiple myeloma treated with B-cell mature antigen-targeted universal chimeric antigen receptor T cells.2023MedicineFree full text
  17. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma.2023Nature communicationsFree full text
  18. Apparent diffusion coefficient measurements of bone marrow infiltration patterns in multiple myeloma for the assessment of tumor burden - a feasibility study.2023Radiology and oncologyFree full text
  19. Cystatin C and eGFRCKD-EPI-CysC: novel biomarkers for renal impairment diagnosis and two-year progression-free survival in multiple myeloma.2023Scandinavian journal of clinical and laboratory investigation
  20. Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma.2022American journal of hematology
  21. Successful eradication of central nervous system infiltration of primary plasma cell leukemia by temozolomide.2022Annals of hematology
  22. Pulsatilla saponin A Induces Apoptosis and Differentiation of Myeloma Cells.2021Anti-cancer agents in medicinal chemistry
  23. C3a and C5a facilitates the metastasis of myeloma cells by activating Nrf2.2021Cancer gene therapy
  24. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.2021Cancer medicineFree full text
  25. Inhibition of the Otub1/c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis.2021Cell communication and signaling : CCSFree full text
  26. Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement.2021Frontiers in immunologyFree full text
  27. Quantitative evaluation of bone marrow infiltration using dual-energy spectral computed tomography in patients with multiple myeloma.2021Journal of X-ray science and technology
Chinese-language papers (not in the count)19
  1. [Renal response and prognosis of newly diagnosed patients with multiple myeloma with renal impairment applying VRD and autologous hematopoietic stem cell transplantation].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  2. [Effect of Recombinant Human Thrombopoietin on Platelet Reconstitution after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma].2024Zhongguo shi yan xue ye xue za zhi
  3. [Interpretation of minimal residual disease for response evaluation in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].2024Zhonghua nei ke za zhi
  4. [Interpretation of risk stratification in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].2024Zhonghua nei ke za zhi
  5. [Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma].2023Zhonghua nei ke za zhi
  6. [Clinical significance and pathogenesis analysis of Moesin in multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  7. [Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  8. [Comparison of next-generation flow cytometry and next-generation sequencing in the assessment of minimal residual disease in multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  9. [The Role of Whole Body DWI in the Evaluation of Bone Disease in Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  10. [Efficacy of total oral regimens containing ixazomib in patients with relapsed and refractory multiple myeloma].2022Zhonghua nei ke za zhi
  11. [Efficacy and safety of lenalidomide combined with bortezomib and dexamethasone induction therapy in newly diagnosed patients with multiple myeloma].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  12. [Multiple myeloma with chromothripsis: three cases report].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  13. [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  14. [The expression level of secretory mature B cell surface antigen in primary diagnosed multiple myeloma and its clinical significance].2022Zhonghua yi xue za zhi
  15. [Preliminary exploration of the metabolic profile and metabolic pathways in newly diagnosed multiple myeloma].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  16. [Application of Conditioning Regimen with Busulfan and Cyclophosphamide in Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi
  17. [The Effects of Chidamide Combined with Anti-myeloma Drugs on the Proliferation and Apoptosis of Myeloma Cells].2021Zhongguo shi yan xue ye xue za zhi
  18. [Clinical Features and Prognostic Factors of Patients with Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi
  19. [Characteristics of immunoglobulin heavy-chain gene clonal rearrangements by next-generation sequencing of patients with multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status49
  1. A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd RegimenNot yet recruitingNCT07709884Lead sponsorPhase 4Start 2026-07
  2. Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple MyelomaRecruitingNCT07652138Lead sponsorPhase 1Start 2025-07
  3. A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell LeukemiaRecruitingNCT06730256Lead sponsorEarly phase 1Start 2025-07
  4. Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) PatientsRecruitingNCT06682156Lead sponsorStart 2024-09
  5. Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingNCT06409702Lead sponsorPhase 4Start 2024-06
  6. Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma PatientsRecruitingNCT04025450Lead sponsorPhase 1/Phase 2Start 2019-07
  7. Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple MyelomaRecruitingNCT03196414Lead sponsorPhase 1/Phase 2Start 2016-09
  8. An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple MyelomaWithdrawnNCT05980507Lead sponsorPhase 1Start 2023-10
  9. Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma PatientsStatus unknownNCT05855122Lead sponsorPhase 4Start 2023-04
  10. CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaStatus unknownNCT05822037Lead sponsorN/AStart 2023-04
  11. This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.Status unknownNCT05486975Lead sponsorEarly phase 1Start 2022-08
  12. Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#CompletedNCT05270928Lead sponsorPhase 1Start 2022-04
  13. Cohort Construction and Prognostic Model Construction for Multiple MyelomaActive, not recruitingNCT06366802Lead sponsorStart 2022-05
  14. A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05066022Lead sponsorN/AStart 2021-10
  15. Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMMStatus unknownNCT04677452Lead sponsorPhase 1Start 2020-12
  16. A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma PatientsCompletedNCT07206810Lead sponsorStart 2018-08
  17. Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCTActive, not recruitingNCT03455972Lead sponsorPhase 1/Phase 2Start 2018-02
  18. Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) PatientsStatus unknownNCT04287660Lead sponsorPhase 3Start 2017-10
  19. PDD vs PAD to Treat Initially Diagnosed MMStatus unknownNCT02577783Lead sponsorPhase 4Start 2015-10
  20. Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in ChinaStatus unknownNCT01812096Lead sponsorPhase 1/Phase 2Start 2014-05
  21. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  22. A Phase I Study of SHR-3836 in Patients With Multiple MyelomaRecruitingNCT07490613Study sitePhase 1Start 2026-06
  23. To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07454187Study sitePhase 1/Phase 2Start 2026-04
  24. Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07529782Study sitePhase 1Start 2026-03
  25. A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple MyelomaRecruitingNCT07760454Study sitePhase 1/Phase 2Start 2026-09
  26. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsRecruitingNCT06508983Study sitePhase 3Start 2024-06
  27. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT06083207Study sitePhase 1/Phase 2Start 2024-07
  28. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10
  29. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Study sitePhase 3Start 2022-11
  30. A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04634552Study sitePhase 2Start 2021-02
  31. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  32. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  33. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  34. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  35. A Study of NINLARO® in Chinese Adults With Multiple MyelomaActive, not recruitingNCT05013190Study siteStart 2021-10
  36. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04674514Study sitePhase 1/Phase 2Start 2021-04
  37. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05
  38. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  39. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  40. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  41. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  42. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT03215030Study sitePhase 1/Phase 2Start 2017-10
  43. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  44. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03
  45. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  46. An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma ParticipantsTerminatedNCT02761187Study siteStart 2016-07
  47. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Study sitePhase 3Start 2013-07
  48. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Study sitePhase 2Start 2012-09
  49. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Study sitePhase 2Start 2010-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 12 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 5.3%.

Papers led
12
2021–2025
Trials led
19
any status, ClinicalTrials.gov
Open trials led
10
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 7720242025: 222025

2 hospitals in Suzhou for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 10

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07854652

    Age 14 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  2. Recruiting
    Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06985485

    Age 15 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  3. Recruiting
    Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT07564453

    Age 15 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  4. Recruiting
    RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06250959

    Age 15 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  5. Recruiting
    Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06393985

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  6. Recruiting
    Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
    Phase
    Phase 1
    Started
    2024-04
    Registry
    NCT06507514

    Age 15 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  7. Recruiting
    Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT06696833

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  8. Recruiting
    CAV Regimen for R/R Ph- B-ALL
    Phase
    N/A
    Started
    2022-10
    Registry
    NCT05657652

    Age 15 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  9. Not yet recruiting
    U96-CAR-T-Cells For R/R B-ALL
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07511426

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  10. Not yet recruiting
    Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
    Phase
    Early phase 1
    Started
    2024-09
    Registry
    NCT06559644

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChildrenAntibody & targeted drugsCAR-T & cell therapy
Papers it led12
  1. Shorter Duration of Blinatumomab Administration to 14 Days Has Same Efficacy and Safety Profile in Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.2025Acta haematologica
  2. A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphob2025CancerFree full text
  3. Genetic and clinical characteristics of acute B-cell lymphoblastic leukemia with MEF2D fusions and report of two novel MEF2D rearrangements.2024Annals of hematology
  4. Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease.2024Blood cancer journalFree full text
  5. Reduced-dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B-cell acute lymphoblastic leukemia.2024Cancer medicineFree full text
  6. Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  7. Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia.2024Investigational new drugsFree full text
  8. Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial.2024Journal of hematology & oncologyFree full text
  9. Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.2024Leukemia research
  10. Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?2023Blood cancer journalFree full text
  11. CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and E2023Clinical and translational medicineFree full text
  12. Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration.2023Frontiers in immunologyFree full text
Chinese-language papers (not in the count)4
  1. [Clinical analysis of 7 cases of acute B cell lymphoblastic leukemia with t (17;19) (q21-22;p13)/TCF3-HLF fusion].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  2. [Clinical efficacy and safety of blinatumomab bridging CAR-T cell therapy in the treatment of patients with adult acute B-cell lymphoblastic leukemia].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  3. [Effect of MXRA7 on the Biological Functions of Acute B Lymphoblastic Leukemia Cell Line REH].2023Zhongguo shi yan xue ye xue za zhi
  4. [Ph-like B-cell acute lymphoblastic leukemia with ZEB2-JAK2 fusion gene positivity: a case report].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status23
  1. U96-CAR-T-Cells For R/R B-ALLNot yet recruitingNCT07511426Lead sponsorPhase 1Start 2026-07
  2. BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic LeukemiaRecruitingNCT07854652Lead sponsorPhase 1Start 2026-09
  3. Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline ChemotherapyRecruitingNCT06985485Lead sponsorPhase 2Start 2025-05
  4. Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic LeukemiaRecruitingNCT07564453Lead sponsorPhase 2Start 2025-04
  5. Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute LeukemiaNot yet recruitingNCT06559644Lead sponsorEarly phase 1Start 2024-09
  6. Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALLRecruitingNCT06507514Lead sponsorPhase 1Start 2024-04
  7. Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic LeukemiaRecruitingNCT06696833Lead sponsorEarly phase 1Start 2024-12
  8. Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALLRecruitingNCT06393985Lead sponsorPhase 2Start 2024-04
  9. CAV Regimen for R/R Ph- B-ALLRecruitingNCT05657652Lead sponsorN/AStart 2022-10
  10. Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALLSuspendedNCT06985498Lead sponsorPhase 2Start 2025-06
  11. CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).Status unknownNCT06078306Lead sponsorPhase 2Start 2024-04
  12. ThisCART19A Bridging to alloHSCT for R/R B-ALLStatus unknownNCT05679687Lead sponsorPhase 1Start 2022-12
  13. Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALLStatus unknownNCT05559450Lead sponsorPhase 2Start 2022-02
  14. CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALLActive, not recruitingNCT05470777Lead sponsorPhase 2Start 2020-01
  15. Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia(R/R-ALL)Status unknownNCT04534634Lead sponsorPhase 2Start 2019-04
  16. CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic LeukemiaActive, not recruitingNCT03984968Lead sponsorPhase 1/Phase 2Start 2017-07
  17. CAR-T Cell Therapy Targeting to CD19 for R/R ALLActive, not recruitingNCT03919240Lead sponsorPhase 1/Phase 2Start 2015-12
  18. RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.RecruitingNCT06250959Lead (inferred)Phase 2Start 2024-02
  19. Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALLCompletedNCT05557110Lead (inferred)Phase 2Start 2022-09
  20. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Study sitePhase 1/Phase 2Start 2021-01
  21. CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.Status unknownNCT03614858Study sitePhase 1/Phase 2Start 2017-09
  22. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT03476239Study sitePhase 3Start 2017-10
  23. CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic LeukemiaStatus unknownNCT03064269Study sitePhase 1Start 2017-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 11 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 2.7%.

Papers led
11
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 0020232024: 3320242025: 002025

3 hospitals in Suzhou for aplastic anaemia63 hospitals in China for aplastic anaemia

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07400341

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  2. Recruiting
    A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
    Phase
    N/A
    Started
    2025-10
    Registry
    NCT07499284

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow University; 2 listed hospitals as study sitesHangzhou, Suzhou, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStem cell transplantImmunosuppressive treatmentChildren
Papers it led11
  1. Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence.2024Annals of hematology
  2. First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study.2024Bone marrow transplantation
  3. The Role of Pre-existing Anti-HLA Antibodies in Severe Aplastic Anemia Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation.2024Transplantation and cellular therapy
  4. Severe aplastic anemia patients with infection who received an allogeneic hematopoietic stem cell transplantation had a better chance: Long-term outcomes of a multicenter study.2022Frontiers in immunologyFree full text
  5. Comparison of Haploidentical Hematopoietic Stem Cell Transplant With or Without Unrelated Cord Blood Infusion in Severe Aplastic Anemia: Outcomes of a Multicenter Study.2022Frontiers in immunologyFree full text
  6. Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study.2022Journal of hematology & oncologyFree full text
  7. Lessons from a patient with severe aplastic anemia complicated with COVID-19.2021Asian journal of surgeryFree full text
  8. Outcomes of severe aplastic anemia patients with infection proceeding with allogeneic hematopoietic stem cell transplantation, versus patients without infection.2021Bone marrow transplantation
  9. A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia.2021Hematology (Amsterdam, Netherlands)
  10. Comparison of 2 Different Rabbit Anti-Thymocyte Globulin (r-ATG) Preparations: Thymocyte r-ATG versus T Lymphoblast Cell Line r-ATG in Allogeneic Hematopoietic Stem Cell Transplantation for Acquired Severe Aplastic Anemia: Propensity Score-2021Transplantation and cellular therapy
  11. First-Line Unrelated Double-Unit Umbilical Cord Blood Transplantation for Acquired Severe Aplastic Anemia.2021Transplantation proceedings
Chinese-language papers (not in the count)3
  1. [The effect of cytomegalovirus and EB virus activation on hematopoietic reconstitution after intensive immunosuppressive therapy for severe aplastic anemia].2025Zhonghua nei ke za zhi
  2. [Positive rates and distribution characteristics of pre-existing anti-human-leukocyte-antigen antibodies in patients with different hematological diseases].2024Zhonghua yi xue za zhi
  3. [Sibling hematopoietic stem cell transplantation for treatment of severe aplastic anemia complicated with antiphospholipid syndrome: a case report].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AARecruitingNCT07400341Lead sponsorPhase 2Start 2026-01
  2. A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic AnemiaRecruitingNCT07499284Lead sponsorN/AStart 2025-10
  3. GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCTStatus unknownNCT05510505Lead sponsorPhase 2Start 2021-12

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 6 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 1.5%.

Papers led
6
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 3320242025: 112025

2 hospitals in Suzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
    Phase
    Phase 4
    Started
    2025-11
    Registry
    NCT07270835

    Age 14 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  2. Not yet recruiting
    Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
    Phase
    Phase 2/Phase 3
    Started
    2025-06
    Registry
    NCT06951971

    Age 1 year to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesTreatment regimensEBV & infection triggersStem cell transplant
Papers it led6
  1. Low-dose emapalumab combined with chemotherapy for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.2025Transplant immunology
  2. Combined emapalumab and ruxolitinib in patients with haemophagocytic Lymphohistiocytosis.2024Blood cancer journalFree full text
  3. Myelodysplastic syndrome associated-haemophagocytic lymphohistiocytosis: A retrospective study of 15 cases in a single centre.2024British journal of haematology
  4. Successful Treatment of Refractory EBV-Associated Hemophagocytic Lymphohistiocytosis with Combined Emapalumab and PD-1 Blockade.2024Journal of clinical immunology
  5. An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis.2023Annals of hematology
  6. Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis.2023Frontiers in immunologyFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic LymphohistiocytosisNot yet recruitingNCT06951971Lead sponsorPhase 2/Phase 3Start 2025-06
  2. Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaRecruitingNCT07270835Lead sponsorPhase 4Start 2025-11
  3. Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line TherapyStatus unknownNCT05039580Lead sponsorPhase 4Start 2021-05
More papers found outside PubMed (not counted)5
  1. Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis2024Bloodconference-abstract
  2. Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients2024Bloodconference-abstract
  3. Myelodysplastic Syndrome Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Study of 15 Cases in a Single Center2023Bloodconference-abstract
  4. The Clinical Significance and Prognostic Value of Serum Beta-2 Microglobulin in Adult Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 326 Patients2023Bloodconference-abstract
  5. Additional file 2 of NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis2022TigerPrints (Clemson University)article

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Suzhou for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 6 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 2.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 1120232024: 1120242025: 112025

2 hospitals in Suzhou for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
    Phase
    Phase 2/Phase 3
    Started
    2024-01
    Registry
    NCT06111638

    Age 18 years to Not stated; men only (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi’an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Over half of these papers are lab or animal studies.

Papers it led6
  1. Macrophage membrane-encapsulated miRNA nanodelivery system for the treatment of hemophilic arthritis.2025Journal of controlled release : official journal of the Controlled Release Society
  2. Incidence of deep venous thrombosis in patients with hemophilia undergoing bilateral simultaneous total knee arthroplasty: a retrospective cohort study.2024BMC musculoskeletal disorders
  3. Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models.2023Blood
  4. Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C.2022Blood advances
  5. The coexistence of antiβ2 glycoprotein 1 antibody antibody has no effect on hemophilia A patient.2022Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  6. No Benefit to Platelet-rich Plasma Over Placebo Injections in Terms of Pain or Function in Patients with Hemophilic Knee Arthritis: A Randomized Trial.2022Clinical orthopaedics and related researchRCT
Earlier papers (2016–2020)1
  1. Refractory lupus nephropathy and acquired Factor VIII and IX deficiencies in a patient with systemic lupus erythematosus treated with rituximab.2017Haemophilia : the official journal of the World Federation of Hemophilia
All its trials on ClinicalTrials.gov, any status8
  1. Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy DrugsRecruitingNCT06111638Study sitePhase 2/Phase 3Start 2024-01
  2. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia ACompletedNCT05707351Study sitePhase 3Start 2023-03
  3. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  4. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)CompletedNCT05082116Study sitePhase 3Start 2021-09
  5. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without InhibitorsCompletedNCT05053139Study sitePhase 3Start 2021-12
  6. A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia ACompletedNCT04565236Study sitePhase 4Start 2020-09
  7. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia ACompletedNCT02492984Study sitePhase 4Start 2015-04
  8. China ADVATE PTP StudyCompletedNCT02170402Study sitePhase 4Start 2014-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 5 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 7.8%.

Papers led
5
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 0020242025: 002025

1 hospital in Suzhou for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Construction of a Database for TTP
    Phase
    Not given
    Started
    2022-10
    Registry
    NCT05571774

    Age not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led5
  1. Association between N-acetylcysteine treatment and in-hospital mortality in adult patients with acquired thrombotic thrombocytopenic purpura: a cohort study.2023Annals of hematology
  2. Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.2023Expert review of hematology
  3. Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment.2022British journal of haematology
  4. Prognostic value of dynamic cardiac biomarkers in patients with acquired refractory thrombocytopenic purpura: A retrospective study in Chinese population.2022Journal of clinical laboratory analysis
  5. Clinical characteristics and outcomes of adult patients with acquired thrombotic thrombocytopenic purpura: a single center retrospective study.2021Annals of palliative medicine
Chinese-language papers (not in the count)5
  1. [The combined regimen based on obinutuzumab plus glucocorticoid for 4 cases of relapsed iTTP].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  2. [Relapsed immune thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus: a case report and literature review].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  3. [A combined regimen based on bortezomib and glucocorticoids for 6 patients with recurrent/refractory immune thrombotic thrombocytopenic purpura].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  4. [Clinical diagnosis and treatment of hereditary thrombocytopenia and purpura: a report of five cases and literature review].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  5. [Research Advance in Treatment of Thrombotic Thrombocytopenic Purpura --Review].2022Zhongguo shi yan xue ye xue za zhi
Earlier papers (2016–2020)5
  1. Novel mutations in ADAMTS13 CUB domains cause abnormal pre-mRNA splicing and defective secretion of ADAMTS13.2020Journal of cellular and molecular medicine
  2. [Effect of Recombinant Protein in the Spacer Domain on ADAMTS13 Activity].2019Zhongguo shi yan xue ye xue za zhi
  3. [Research Advances of Acquired Thrombotic Thrombocytopenic Purpura--Review].2018Zhongguo shi yan xue ye xue za zhi
  4. [The diagnostic value of PLASMIC score in the discrimination between thrombotic thrombocytopenic purpura and disseminated intravascular coagulation].2018Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  5. [Progress of acquired thrombotic thrombocytopenic purpura].2017Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
All its trials on ClinicalTrials.gov, any status2
  1. Construction of a Database for TTPRecruitingNCT05571774Lead sponsorStart 2022-10
  2. A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic PurpuraActive, not recruitingNCT04683003Study sitePhase 3Start 2021-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 10 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 2.1%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 2220232024: 3320242025: 112025

1 hospital in Suzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesBiologic drugsImagingRelapse prevention
Departments in papersNeurologyRadiology / nuclear medicineNeurosurgery
Papers it led10
  1. Exploring the causal role of gut microbiota and inflammatory proteins in neuromyelitis optica spectrum disorder: A Mendelian randomization study with mediation analysis.2025MedicineFree full text
  2. Correlation of GABA+ levels in the medial prefrontal cortex and circulating follicular helper T cells in neuromyelitis optica spectrum disorder patients with cognitive impairment.2024Brain and behaviorFree full text
  3. Vitamin D status and neuromyelitis optica spectrum disease: A systematic review and meta-analysis.2024Clinical neurology and neurosurgery
  4. Aberrant hippocampal intrinsic morphological connectivity patterns in Neuromyelitis optica spectrum disorder with cognitive impairment: Insights from an individual-based morphological brain network.2024Multiple sclerosis and related disorders
  5. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.2023Journal of neurologyFree full text
  6. B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study.2023Multiple sclerosis and related disorders
  7. Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.2022Multiple sclerosis and related disorders
  8. Altered functional connectivity associated with cognitive impairment in neuromyelitis optica spectrum disorder.2022Multiple sclerosis and related disorders
  9. Reduced GABA levels in the medial prefrontal cortex are associated with cognitive impairment in patients with NMOSD.2022Multiple sclerosis and related disorders
  10. Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study.2021Journal of the neurological sciences
All its trials on ClinicalTrials.gov, any status1
  1. A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune DiseasesWithdrawnNCT06869278Study sitePhase 1Start 2025-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 9 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 1.8%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 3320242025: 112025

1 hospital in Suzhou for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisBiologic & complement drugsStandard immunotherapy
Departments in papersNeurologyNeurosurgeryRheumatology & immunology
Papers it led9
  1. Relative change rate of anti-acetylcholine receptor antibodies concentration Correlates with the recurrence of myasthenia gravis in AChR-Abs-positive patients.2025Clinica chimica acta; international journal of clinical chemistry
  2. Expression of lymphocyte activation gene-3 on CD4+T cells is regulated by cytokine interleukin-18 in myasthenia gravis.2024Journal of neuroimmunology
  3. The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.2024Journal of neurology
  4. Neurometabolic and Brain Functional Alterations Associated with Cognitive Impairment in Patients with Myasthenia Gravis: A Combined 1H-MRS and fMRI Study.2024Neuroscience
  5. Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis.2023Frontiers in immunologyFree full text
  6. Association between myasthenia gravis and cognitive disorders: a PRISMA-compliant meta-analysis.2023The International journal of neuroscience
  7. Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis.2022Journal of immunology researchFree full text
  8. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.2022Journal of neuroimmunology
  9. Primary biliary cirrhosis associated with myasthenia gravis after postpartum: a case report.2021Journal of medical case reportsFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  2. A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune DiseasesWithdrawnNCT06869278Study sitePhase 1Start 2025-06
  3. Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Study sitePhase 3Start 2023-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 3 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

1 hospital in Suzhou for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesGeneticsRevascularisation surgeryImaging & blood flow
Departments in papersNeurosurgeryRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 2 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 1.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Suzhou for Wilson disease28 hospitals in China for Wilson disease

No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics (ATP7B)Liver disease & transplant

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

3 hospitals in Suzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Suzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Registry
    NCT06726577

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Suzhou for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Adult Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05618379Study siteStart 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 3 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 4.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

3 hospitals in Suzhou for Fabry disease85 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07187440

    Age 7 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

2 hospitals in Suzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

3 hospitals in Suzhou for Behçet disease149 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11
  2. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedNCT04609397Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

7 hospitals in Suzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Suzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunologyNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Suzhou for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

苏州大学附属第一医院

First Affiliated Hospital of Soochow University

苏州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
First Affiliated Hospital of Soochow University-; first Affiliated Hospital of Soochow University; China The First Affiliated Hospital of Soochow University; First Affiliated Hospital of Soochow University. Suzhou; Zhangjiagang First Affiliated Hospital of Soochow University

Suggest a correctionDownload the data